Marinomed has set the offer price for its IPO at Vienna Stock Exchange at the lower limit of €75 per new share.
Novozymes has entered into a partnership with French Carbios and its subsidiary Carbiolice, which aim to launch degradable bioplastics with limited lifespan for the packaging industry by 2020.
A new assay that accurately measures how arthritis patients respond to treatment with TNFalpha blockers such as adalimumab, open up the way to predict efficacy.
In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure developers sufficient return on investments (ROI).
Immunoncology and vaccine specialist BioNTech AG is broadening its antibody discovery capabilities by acquiring MAB Discovery‘s antibody generation unit.
Swiss fine chemicals specialist Clariant has hammered out a R&D pact with ExxonMobil and Renewable Energy Group (REG) Inc to combine technologies in order of producing biodiesel from cellulose
The Innovative Medicines Initiative II has earmarked €80m for pre-competetive research improving the pharmaceutical industry’s productivity.
Novo Holdings has invested €18m from its €135m REPAIR Impact Fund into four companies.
Boehringer Ingelheim has expanded its 2014 R&D collaboration with the BioMed X Innovation Center (Heidelberg, Germany) to find new treatment approaches for early intervention of psychiatric diseases.
Canadian and Finnish researchers have demonstrated that long immune cell contact to lung tissue turns tissue repair into fibrosis.